Synaptic Loss in Multiple System Atrophy

Sponsor
University of Exeter
Study ID
NCT05121012
Status
Recruiting
Apply to this trial

Conditions

  • Multiple System Atrophy
  • Progressive Supranuclear Palsy (PSP)

Eligibility Criteria

Sex
ALL
Age
45 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Study procedures for MSA patients — OTHER
    The group of MSA patients will undergo a collection of demographic data, a neurological examination with administration of clinical scales relevant for MSA, and a collection of venous blood sample for routine and biomarker analyses. Participants will undergo one PET scan with the tracer \[11C\]UCB-J, and one PET scan with the tracer \[18F\]FDG. All participants will also undergo one MRI scan. Participants will also undergo one lumbar puncture (optional). All procedures will be performed at baseline and after one-year follow-up. A subgroup of patients with MSA will also undergo, at one time point only, one PET scan with the tracer \[18F\]APN107.
  • Study procedures for PSP patients — OTHER
    The group of PSP patients will undergo a collection of demographic data, a neurological examination with administration of clinical scales relevant for PSP, and a collection of venous blood sample for routine and biomarker analyses. Participants will undergo one PET scan with the tracer \[18F\]APN107 and one MRI scan. All procedures will be performed at baseline and after one-year follow-up.

Study Details

In this study the investigators would like to investigate the degree of damage of the synapses, an important part of the neurons vital for the communications between neurons, in Multiple System Atrophy (MSA), and pathology related to abnormal accumulation of a protein named tau, in Progressive Supranuclear Palsy (PSP).

Key Dates

First listed
Nov 16, 2021
Start date
Sep 1, 2021
Status verified
Feb 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
36 participants (estimated)

Arms

  • Arm: Patients with MSA
    Patients with a diagnosis of MSA and either a clinical form MSA-C or MSA-P
  • Arm: Patients with Progressive Supranuclear Palsy
    Patients with a diagnosis of PSP, either the clinical forms PSP-RS or PSP-P

Primary Outcome Measure

To measure the magnitude of longitudinal within-group change in [11C]UCB-J volume of distribution in MSA [ Time Frame: Baseline to 12 Months ]

Central Contacts

Related Studies